USA flag logo/image

An Official Website of the United States Government

Developing a plectin-1 targeted imaging agent for the detection of pancreatic…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43CA162845
Solicitation Year:
2011
Solicitation Topic Code:
NCI
Solicitation Number:
PA10-050
Small Business Information
ITI HEALTH, INC.
1076 AUTUMN HILL CT CROZET, VA 22932-3140
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Developing a plectin-1 targeted imaging agent for the detection of pancreatic can
Agency: HHS
Contract: 1R43CA162845-01
Award Amount: $299,999.00
 

Abstract:

DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) is an intractable clinical problem, typically presenting with metastasis at the time of diagnosis and exhibiting profound resistance to existing therapies. Currently, the standarddiagnostic course includes CT or MRI scans which do not have optimal sensitivity and specificity for accurately diagnosing and determining resectability status. The long-term objectives of this project are to develop an imaging agent that can sensitivelyand accurately detect pancreatic cancer. To that end, we are developing a targeted imaging agent to the newly identified pancreatic cancer cell surface biomarker plectin-1. Plectin-1 is specifically expressed in pancreatic cancer and not in benign inflamedconditions. It is upregulated during carcinogenesis and expressed at high levels in the advanced premetastatic PanIN III lesions. Moreover, a SPECT/CT plectin-1 targeted imaging agent has been developed and validated in numerous stringent mouse models. Experiments will be performed to optimize the imaging agent's molecular configuration and imaging modality. Outcomes will lead to a lead imaging product that will be advanced to phase II for commercial product development and clinical study. PUBLIC HEALTH RELEVANCE: The overall goal of this project is to develop new imaging approaches for the detection of pancreatic cancer, determine cancer resectability status and monitor response to chemotherapy. Alternative uses include early diagnostic screening inindividuals with high-risk for the development of pancreatic cancer. We will do this by chemically synthesizing imaging agents and testing them in mouse models of pancreatic cancer. We will also test whether PET or SPECT imaging has the best characteristics for imaging pancreatic cancer.

Principal Investigator:

Greg B. Fralish
434-298-4844
gfralish@itihealth.com

Business Contact:

Greg Fralish
434-298-4844
gfralish@itihealth.com
Small Business Information at Submission:

ITI HEALTH, INC.
1076 AUTUMN HILL CT CROZET, VA 22932-3140

EIN/Tax ID: 127395359
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No